IMC Chicago
RARE icon

IMC Chicago’s Ultragenyx Pharmaceutical RARE Stock Holding History

IMC Chicago’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$618K Sell
18,500
-24,200
-57% -$601K ﹤0.01% 4404
2026
Q1 		$895K Buy
42,700
+29,600
+226% +$667K ﹤0.01% 3388
2025
Q4 		$301K Buy
+13,100
New +$431K ﹤0.01% 3799

Other funds holding RARE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

IMC Chicago's RARE Position: Q2 2026 in Review

IMC Chicago increased its Ultragenyx Pharmaceutical (RARE) stake by 114% in Q2 2026, buying an estimated $338K and bringing the position to 25,535 shares worth $853K. The position accounts for ﹤0.01% of the portfolio, ranked #4050.

IMC Chicago first reported a position in RARE in Q4 2025 and has held it in 3 quarters since. 311 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

  • IMC Chicago held 25,535 shares of Ultragenyx Pharmaceutical worth $853K as of Q2 2026.
  • IMC Chicago bought 13,616 Ultragenyx Pharmaceutical shares in Q2 2026, an estimated $338K.
  • Ultragenyx Pharmaceutical made up ﹤0.01% of IMC Chicago's portfolio in Q2 2026, its #4050 holding.
  • IMC Chicago first reported a position in Ultragenyx Pharmaceutical in Q4 2025 and has held it in 3 quarters since.
  • 311 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on IMC Chicago's 13F filing for Q2 2026, filed 6 Aug 2026.